Drug-eluting bead transarterial chemoembolization for large recurrent or refractory DLBCL masses

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This retrospective observational analysis reviews adult patients with relapsed or refractory diffuse large B-cell lymphoma who received drug-eluting bead transarterial chemoembolization (DEB-TACE) for bulky lesions. Eligible lesions are ≥5 cm with imaging evidence of abundant blood supply and patients previously showed at least some response to doxorubicin-based therapy; laboratory and performance status limits are applied. The study extracts radiographic response, symptom relief, procedure-related complications, and survival outcomes from medical records with predefined follow-up intervals. Findings are intended to provide preliminary safety and efficacy data to support future larger multicenter prospective trials.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* (1) Age 18 to 75 years; (2) Pathologically confirmed diffuse large B-cell lymphoma (DLBCL); (3) Recurrence or treatment resistance following multiple therapeutic regimens (e.g., chemotherapy, immunotherapy, targeted therapy), with at least one clearly defined bulky lesion (maximum diameter ≥5 cm or imaging evidence of bulky lesion); (4) Imaging studies (CT, MRI, or PET-CT) confirm rich blood supply to the lesion, making it suitable for transarterial interventional therapy; (5) History of favorable response to doxorubicin-based agents during prior systemic therapy; (6) ECOG performance status ≤ 2; (7) Blood counts, hepatic and renal function, and coagulation parameters meet the following criteria:

  * Platelet count ≥ 30 × 10\^9/L;
  * Total bilirubin ≤ 1.5 times the upper limit of normal (ULN);
  * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 times the ULN;
  * Serum creatinine ≤ 2.5 times the upper limit of normal (ULN);
  * Prothrombin time international normalized ratio (INR) ≤ 1.5. (8) The patient has previously undergone at least one DEB-TACE treatment at this institution.

Exclusion Criteria:

* (1) Patients with severe cardiac, pulmonary, hepatic, or renal dysfunction, or other serious comorbidities rendering them unable to tolerate interventional therapy; (2) Patients with active or uncontrolled severe infections; (3) Patients with severe coagulation disorders or bleeding tendencies; (4) Pregnant or lactating women, or patients planning pregnancy during the study period; (5) Allergy or contraindications to drug-eluting microsphere materials or chemotherapy drugs; (6) Psychiatric disorders or cognitive impairment preventing treatment compliance and follow-up; (7) Other conditions deemed unsuitable for study participation by the investigator.

Where it's running

• The First Affiliated Hospital of Fujian Medical University
  Fuzhou, Fujian, China Recruiting

Study contacts

• Study coordinator: Xiaoquan ji
• Email: jxqwd0901@163.com
• Phone: +8618159117171

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combining radiation therapy with lenalidomide and glofitamab for treating relapsed DLBCL

  This study is testing a new treatment combining radiation therapy with lenalidomide and glofitamab to see if it helps people with relapsed diffuse large B-cell lymphoma who haven't responded to other treatments.

  Recruiting Phase 2 The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT06651853

• Polatuzumab Vedotin plus Rituximab with Reduced-dose chemo for frail seniors with DLBCL

  This trial tests whether a gentler, first-line treatment (Polatuzumab Vedotin with Rituximab and reduced-dose chemo) helps older, frail patients with DLBCL stay disease-free longer.

  Recruiting Phase 4 The First Hospital of Jilin University · Changchun, Jilin · NCT07908888

• Glofitamab combo vs Rituximab combo with chemo for relapsed/refractory DLBCL

  This study tests whether glofitamab with chemotherapy (JS203-GemOx) helps patients with relapsed or refractory DLBCL more than rituximab with chemotherapy.

  Recruiting Phase 3 Shanghai Junshi Bioscience Co., Ltd. · Beijing, Beijing Municipality · NCT07808827

• Non-Hodgkin Lymphoma Sample Collection for MRD Testing

  This study tests a blood-based and tissue-based approach to see if a molecular residual disease test can detect lingering cancer in adults with aggressive NHL who are starting standard therapy.

  Recruiting Natera, Inc. · Austin, Texas · NCT07750886

• External beam radiation followed by bispecific antibody therapy for relapsed or refractory DLBCL

  This study tests whether giving targeted radiation first, then bispecific antibodies (epcoritamab or glofitamab), is tolerable for adults with relapsed or refractory diffuse large B-cell lymphoma.

  Recruiting Phase 1 University of Utah · Salt Lake City, Utah · NCT07528352

• Chidamide maintenance for MRD-positive double-expressor DLBCL in first remission

  This study tests whether giving chidamide as maintenance therapy can help people with double-expressor DLBCL who have complete remission but still have MRD detected in their blood.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07507318

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.